Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
20.04
+0.25 (1.26%)
At close: Nov 22, 2024, 4:00 PM
20.00
-0.04 (-0.20%)
After-hours: Nov 22, 2024, 6:09 PM EST
Aligos Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Cash & Equivalents | 35.33 | 135.7 | 81.35 | 186.82 | 220.38 | 69.57 | Upgrade
|
| Short-Term Investments | 39.59 | - | 44.48 | 3.92 | 23.13 | 48.1 | Upgrade
|
| Cash & Short-Term Investments | 74.92 | 135.7 | 125.83 | 190.73 | 243.51 | 117.66 | Upgrade
|
| Cash Growth | 6.38% | 7.85% | -34.03% | -21.67% | 106.96% | 29.51% | Upgrade
|
| Restricted Cash | 0.11 | 0.07 | 0.12 | 0.16 | 0.56 | 0.54 | Upgrade
|
| Other Current Assets | 4.79 | 5.31 | 7.6 | 13.53 | 5.94 | 2.03 | Upgrade
|
| Total Current Assets | 79.82 | 141.08 | 133.55 | 204.42 | 250.02 | 120.23 | Upgrade
|
| Property, Plant & Equipment | 7.97 | 9.82 | 12.51 | 14.97 | 14.91 | 16.09 | Upgrade
|
| Long-Term Investments | - | - | - | 15.11 | - | 10.02 | Upgrade
|
| Other Long-Term Assets | 0.64 | 0.63 | 0.63 | 0.87 | 0.38 | 0.19 | Upgrade
|
| Total Assets | 88.43 | 151.53 | 146.69 | 235.37 | 265.3 | 146.52 | Upgrade
|
| Accounts Payable | 2.74 | 2.52 | 4.74 | 3.02 | 3.31 | 3.77 | Upgrade
|
| Accrued Expenses | 14.16 | 16.84 | 16.04 | 25.39 | 16.56 | 7.6 | Upgrade
|
| Current Portion of Leases | 3.4 | 3.24 | 3.14 | 2.91 | 2.51 | 2.45 | Upgrade
|
| Current Unearned Revenue | 0.66 | 1.31 | 9.21 | 7.64 | 7.89 | - | Upgrade
|
| Total Current Liabilities | 20.96 | 23.91 | 33.13 | 38.96 | 30.27 | 13.82 | Upgrade
|
| Long-Term Leases | 5.73 | 7.9 | 9.43 | 11.55 | 10.5 | 11.88 | Upgrade
|
| Long-Term Unearned Revenue | - | - | 0.23 | - | 4.11 | - | Upgrade
|
| Other Long-Term Liabilities | 11.64 | 27.64 | - | 0.13 | 0.38 | 3.64 | Upgrade
|
| Total Liabilities | 38.33 | 59.45 | 42.79 | 50.64 | 45.26 | 29.33 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0 | 0 | 0 | - | Upgrade
|
| Additional Paid-In Capital | 585.37 | 578.33 | 502.61 | 487.35 | 394.96 | 1.42 | Upgrade
|
| Retained Earnings | -535.86 | -486.8 | -399.12 | -303.07 | -174.74 | -66.2 | Upgrade
|
| Comprehensive Income & Other | 0.58 | 0.55 | 0.4 | 0.45 | -0.19 | -0.12 | Upgrade
|
| Total Common Equity | 50.1 | 92.08 | 103.9 | 184.73 | 220.04 | -64.89 | Upgrade
|
| Shareholders' Equity | 50.1 | 92.08 | 103.9 | 184.73 | 220.04 | 117.19 | Upgrade
|
| Total Liabilities & Equity | 88.43 | 151.53 | 146.69 | 235.37 | 265.3 | 146.52 | Upgrade
|
| Total Debt | 9.13 | 11.14 | 12.57 | 14.46 | 13.01 | 14.33 | Upgrade
|
| Net Cash (Debt) | 65.79 | 124.57 | 113.25 | 176.28 | 230.51 | 103.33 | Upgrade
|
| Net Cash Growth | 12.16% | 9.99% | -35.75% | -23.53% | 123.07% | 34.22% | Upgrade
|
| Net Cash Per Share | 11.02 | 48.46 | 66.31 | 110.57 | 576.95 | 1287.03 | Upgrade
|
| Filing Date Shares Outstanding | 3.59 | 3.03 | 1.72 | 1.71 | 1.53 | 0.16 | Upgrade
|
| Total Common Shares Outstanding | 3.32 | 3 | 1.72 | 1.71 | 1.52 | 0.16 | Upgrade
|
| Working Capital | 58.87 | 117.18 | 100.42 | 165.47 | 219.74 | 106.41 | Upgrade
|
| Book Value Per Share | 15.07 | 30.65 | 60.52 | 108.18 | 144.30 | -413.02 | Upgrade
|
| Tangible Book Value | 50.1 | 92.08 | 103.9 | 184.73 | 220.04 | -64.89 | Upgrade
|
| Tangible Book Value Per Share | 15.07 | 30.65 | 60.52 | 108.18 | 144.30 | -413.02 | Upgrade
|
| Machinery | 8.01 | 7.91 | 8.28 | 7.48 | 6.23 | 4.82 | Upgrade
|
| Construction In Progress | 0 | 0 | 0.02 | 0.02 | 0.07 | 0.11 | Upgrade
|
| Leasehold Improvements | 6.1 | 6.1 | 6.09 | 5.94 | 5.66 | 5.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.